Synthesis of 5-nitro-2-furancarbohydrazides and their cis- diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 7024-7039

  Millet, Régis ^a,f   Urig, Sabine ^b   Jacob, Judit ^e   Amtmann, Eberhard ^c   Moulinoux, Jacques Philippe ^d   Gromer, Stephan ^e   Becker, Katja ^b   Davioud Charvet, Elisabeth ^a,e  

^a INSTITUT PASTEUR DE LILLE   (France)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITÉ DE RENNES 1   (France)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 NITRO 2 FURANCARBOHYDRAZIDE DERIVATIVE; CISPLATIN; CISPLATIN DERIVATIVE; CYTOSTATIC AGENT; MUTANT PROTEIN; OXIDOREDUCTASE INHIBITOR; SELENOCYSTEINE; SELENOPROTEIN; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITOR INTERACTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; NONHUMAN; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DROSOPHILA MELANOGASTER; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; HUMANS; HYDRAZINES; KINETICS; MICE; NITROREDUCTASES; ORGANOPLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOREDOXIN REDUCTASE (NADPH); TIME FACTORS;

EID: 27444435579     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050256l     Document Type: Article

References (53)

1. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs. Chem. Rev. 1999, 99, 2451-2466.
2. Reedijk, J. Why does Cisplatin reach Guanine-n7 with competing s-donor ligands available in the cell? Chem. Rev. 1999, 99, 2499-2510.
3. Gromer, S.; Urig, S.; Becker, K. The thioredoxin system-from science to clinic. Med. Res. Rev. 2004, 24, 40-89.
4. Holmgren, A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 1989, 264, 13963-13966.
5. Krnajski, Z.; Gilberger, T. W.; Walter, R. D.; Cowman, A. F.; Muller, S. Thioredoxin reductase is essential for the survival of Plasmodium falciparum erythrocytic stages. J. Biol. Chem. 2002, 277, 25970-25975.
6. Missirlis, F.; Ulschmid, J. K.; Hirosawa-Takamori, M.; Gronke, S.; Schafer, U.; Becker, K.; Phillips, J. P.; Jackle, H. Mitochondrial and cytoplasmic thioredoxin reductase variants encoded by a single Drosophila gene are both essential for viability. J. Biol. Chem. 2002, 277, 11521-11526.
7. Missirlis, F.; Phillips, J. P.; Jackle, H. Cooperative action of antioxidant defense systems in Drosophila. Curr. Biol. 2001, 11, 1272-1277.
8. Jakupoglu, C.; Przemeck, G. K.; Schneider, M.; Moreno, S. G.; Mayr, N.; Hatzopoulos, A. K.; de Angelis, M. H.; Wurst, W.; Bornkamm, G. W.; Brielmeier, M.; Conrad, M. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol. Cell Biol. 2005, 25, 1980-1988.
9. Conrad, M.; Jakupoglu, C.; Moreno, S. G.; Lippl, S.; Banjac, A.; Schneider, M.; Beck, H.; Hatzopoulos, A. K.; Just, U.; Sinowatz, F.; Schmahl, W.; Chien, K. R.; Wurst, W.; Bornkamm, G. W.; Brielmeier, M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol. Cell Biol. 2004, 24, 9414-9423.
10. Anestål, K.; Arnér, E. S. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J. Biol. Chem. 2003, 278, 15966-15972.
11. Sasada, T.; Nakamura, H.; Ueda, S.; Sato, N.; Kitaoka, Y.; Gon, Y.; Takabayashi, A.; Spyrou, G.; Holmgren, A.; Yodoi, J. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic. Biol. Med. 1999, 27, 504-514.
12. Arscott, L. D.; Gromer, S.; Schirmer, R. H.; Becker, K.; Williams, C. H., Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 3621-3626.
13. Gromer, S.; Wissing, J.; Behne, D.; Ashman, K.; Schirmer, R. H.; Flohe, L.; Becker, K. A hypothesis on the catalytic mechanism of the selenoenzyme thioredoxin reductase. Biochem. J. 1998, 332 (Pt 2), 591-592.
14. Zhong, L.; Arnér, E. S.; Ljung, J.; Aslund, F.; Holmgren, A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J. Biol. Chem. 1998, 273, 8581-8591.
15. Lee, S. R.; Bar-Noy, S.; Kwon, J.; Levine, R. L.; Stadtman, T. C.; Rhee, S. G. Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2521-2526.
16. Bauer, H.; Massey, V.; Arscott, L. D.; Schirmer, R. H.; Ballou, D. P.; Williams, C. H., Jr. The mechanism of high Mr thioredoxin reductase from Drosophila melanogaster. J. Biol. Chem. 2003, 278, 33020-33028.
17. Sandalova, T.; Zhong, L.; Lindqvist, Y.; Holmgren, A.; Schneider, G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9533-9538.
18. Kaim, W.; Schwederski, B. Bioanorganische Chemie. Zur Funktion chemischer Elemente in Lebensprozessen, 2nd ed.; Teubner Verlag: Stuttgart, 1995; p 460.
19. Gromer, S.; Arscott, L. D.; Williams, C. H., Jr.; Schirmer, R. H.; Becker, K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady-state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 1998, 273, 20096-20101.
20. Becker, K.; Herold-Mende, C.; Park, J. J.; Lowe, G.; Schirmer, R. H. Human thioredoxin reductase is efficiently inhibited by (2,2′:6′, 2″-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J. Med. Chem. 2001, 44, 2784-2792.
21. Irmler, A.; Bechthold, A.; Davioud-Charvet, E.; Hofmann, V.; Réau, R.; Gromer, S.; Schirmer, R. H.; Becker, K. Bisulfide Reductases -Current Developments. Flavins and Flavoproteins 2002; Agency for Scientific Publications: Berlin, 2002; pp 803-815.
22. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 4046-4050.
23. Pasini, A. A doxorubicin-Pt(II) complex with antitumor activity. Synthesis, characterization and reactions with guanosine and DNA. Gazz. Chim. Ital. 1987, 117, 763-768.
24. Palmer, B. D.; Lee, H. H.; Johnson, P.; Baguley, B. C.; Wickham, G.; Wakelin, L. P.; McFadyen, W. D.; Denny, W. A. DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine. J. Med. Chem. 1990, 33, 3008-3014.
25. Gibson, D.; Gean, K. F.; Ben-Shoshan, R.; Ramu, A.; Ringel, I.; Katzhendler, J. Preparation, characterization, and anticancer activity of a series of cis-PtC12 complexes linked to anthraquinone intercalators. J. Med. Chem. 1991, 34, 414-420.
26. Perez, J. M.; Lopez-Solera, I.; Montero, E. I.; Brana, M. F.; Alonso, C.; Robinson, S. P.; Navarro-Ranninger, C. Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide) complexes. J. Med. Chem. 1999, 42, 5482-5486.
27. von Nussbaum, F.; Miller, B.; Wild, S.; Hilger, C. S.; Schumann, S.; Zorbas, H.; Beck, W.; Steglich, W. Synthesis of 1-(2-amino-phenyl)isoquinolines and the biological activity of their cisdichloro platinum(II) complexes. J. Med. Chem. 1999, 42, 3478-3485.
28. Davioud-Charvet, E.; Becker, K.; Landry, V.; Gromer, S.; Loge, C.; Sergheraert, C. Synthesis of 5,5′-dithiobis(2-nitrobenzamides) as alternative substrates for trypanothione reductase and thioredoxin reductase: a microtiter colorimetric assay for inhibitor screening. Anal. Biochem. 1999, 268, 1-8.
29. Cenas, N. K.; Bironaite, D. A.; Kulys, J. J.; Sikhova, N. M. Interaction of nitrofurans with glutathione reductase. Biochim. Biophys. Acta 1991, 1073, 195-199.
30. Miskiniene, V.; Sarlauskas, J.; Jacquot, J. P.; Cenas, N. Nitro-reductase reactions of Arabidopsis thaliana thioredoxin reductase. Biochim. Biophys. Acta 1998, 1366, 275-283.
31. Gromer, S.; Johansson, L.; Bauer, H.; Arscott, L. D.; Rauch, S.; Ballou, D. P.; Williams, C. H., Jr.; Schirmer, R. H.; Arnér, E. S. Active sites of thioredoxin reductases: why selenoproteins? Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12618-12623.
32. Mau, B. L.; Powis, G. Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Biochem. Pharmacol. 1992, 43, 1613-1620.
33. Arnér, E. S.; Nakamura, H.; Sasada, T.; Yodoi, J.; Holmgren, A.; Spyrou, G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cisdiamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic. Biol. Med. 2001, 31, 1170-1178.
34. Blumenstiel, K.; Schoneck, R.; Yardley, V.; Croft, S. L.; Krauth-Siegel, R. L. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem. Pharmacol. 1999, 58, 1791-1799.
35. Gilberger, T. W.; Bergmann, B.; Walter, R. D.; Muller, S. The role of the C-terminus for catalysis of the large thioredoxin reductase from Plasmodium falciparum. FEBS Lett. 1998, 425, 407-410.
36. Muller, D.; Zeltser, I.; Bitan, G.; Gilon, C. Building units for N-backbone cyclic peptides. 3. Synthesis of protected N(alpha)-(omega- aminoalkyl)amino acids and N(alpha)-(omega-carboxyalkyl)amino acids. J. Org. Chem. 1997, 62, 411-416.
37. Thomas, P.; Finnie, J. K.; Williams, J. G. Feasibility of identification and monitoring of arsenic species in soil and sediment samples by coupled HPLC-inductively coupled plasma mass spectrometry. J. Anal. At. Spectrom. 1997, 12, 1367-1372.
38. Arnér, E. S.; Bjornstedt, M.; Holmgren, A. 1-Chloro-2,4- dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J. Biol. Chem. 1995, 270, 3479-3482.
39. Kitz, R.; Wilson, I. B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 1962, 237, 3245-3249.
40. Kuo, D. J.; Jordan, F. Active site directed irreversible inactivation of brewers' yeast pyruvate decarboxylase by the conjugated substrate analogue (E)-4-(4-chlorophenyl)-2-oxo-3-butenoic acid: development of a suicide substrate. Biochemistry 1983, 22, 3735-3740.
41. Zhong, L.; Holmgren, A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J. Biol. Chem. 2000, 275, 18121-18128.
42. Jansen, B. A.; Brouwer, J.; Reedijk, J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J. Inorg. Biochem. 2002, 89, 197-202.
43. Kearns, P. R.; Hall, A. G. Glutathione and the response of malignant cells to chemotherapy. Drug Discovery Today 1998, 3, 113-121.
44. Baker, A.; Payne, C. M.; Briehl, M. M.; Powis, G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 1997, 57, 5162-5167.
45. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins. Science 1997, 278, 497-499.
46. Kato, Y.; Inouye, T.; Jyosui, S.; Kakimoto, K.; Iyehara-Ogawa, H.; Tsuruta, S. Structure-dependent variation in the mutagenic, prophage-inducing and antibacterial activities of 5-nitro-2-furamide derivatives. Mutat. Res. 1984, 140, 169-174.
47. Nordhoff, A.; Bucheler, U. S.; Werner, D.; Schirmer, R. H. Folding of the four domains and dimerization are impaired by the Gly446→Glu exchange in human glutathione reductase. Implications for the design of antiparasitic drugs. Biochemistry 1993, 32, 4060-4066.
48. Bauer, H.; Kanzok, S. M.; Schirmer, R. H. Thioredoxin-2 but not thioredoxin-1 is a substrate of thioredoxin peroxidase-1 from Drosophila melanogaster: isolation and characterization of a second thioredoxin in D. Melanogaster and evidence for distinct biological functions of Trx-1 and Trx-2. J. Biol. Chem. 2002, 277, 17457-17463.
49. Holmgren, A.; Bjornstedt, M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 1995, 252, 199-208.
50. Salmon-Chemin, L.; Buisine, E.; Yardley, V.; Kohler, S.; Debreu, M. A.; Landry, V.; Sergheraert, C.; Croft, S. L.; Krauth-Siegel, R. L.; Davioud-Charvet, E. 2- and 3-substituted 1,4-naphtho-quinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J. Med. Chem. 2001, 44, 548-565.
51. Gromer, S.; Merkle, H.; Schirmer, R. H.; Becker, K. Human placenta thioredoxin reductase: preparation and inhibitor studies. Methods Enzymol. 2002, 347, 382-394.
52. Amtmann, E.; Zoller, M.; Wesch, H.; Schilling, G. Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum. Cancer Chemother. Pharmacol. 2001, 47, 461-466.
53. Zhong, L.; Arnér, E. S.; Holmgren, A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redoxactive selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5854-5859.